Document:

Amendment to Offer Letter - Hsiao D. Lieu

 EXHIBIT 10.19 
  

					
	 

	 	 115 Sansome Street, Suite #310
 San Francisco, California 94104
	  	 (415) 415-7880 Tel.
 (415) 875-7075 Fax

 10 March 2009 
 Hsiao D. Lieu, M.D., F.A.C.C. 
 2415 Hale Drive 
 Burlingame, CA 94010 
  

	Re:	Amendment to Offer Letter 

 Dear Hsiao: 
 Nile Therapeutics, Inc. (the “Company”) is pleased to offer an amendment to your current terms of employment as set forth in that offer letter
dated February 22, 2008, as amended to date (the “Existing Offer Letter”). Effective upon your agreement with the terms of this letter, the paragraph in the Existing Offer Letter beginning with “For purposes of this letter, a
‘Change in Control’ shall mean . . .” shall be amended and restated in its entirety to read as follows: 
 For purposes of this
letter, a “Change in Control” shall mean a transaction or series of transactions (other than an offering of the Company’s stock to the general public through a registration statement filed with the Securities and Exchange Commission)
whereby any “person” or related “group” of “persons” (as such terms are used in Sections 13(d) and 14(d)(2) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (other than the Company, any
of its subsidiaries, an employee benefit plan maintained by the Company or any of its subsidiaries or a “person” that, prior to such transaction, directly or indirectly controls, is controlled by, or is under common control with, the
Company) directly or indirectly acquires beneficial ownership (within the meaning of Rule 13d-3 under the Exchange Act) of securities of the Company possessing more than 50% of the total combined voting power of the Company’s securities
outstanding immediately after such acquisition. Notwithstanding the foregoing, no transaction shall be considered a Change of Control for the purposes of this letter: (A) if the stockholders existing prior to such transaction(s) hold in the
aggregate more than fifty percent (50%) of the securities or assets of the surviving or resulting company; or (B) in connection with a private placement of equity securities of the Company in connection with a financing of the
Company’s on-going operations. 
 While the Existing Offer Letter with be amended and restated as set forth above, the remainder of your
Existing Offer Letter shall otherwise remain unchanged and in full force and effect. Please indicate your agreement with these terms by signing and dating the enclosed duplicated original of this letter agreement and returning it to me. 

 

			
	Sincerely,
	
	Nile Therapeutics, Inc.
		
	By:	 	/s/ Peter Strumph
		 	Peter Strumph
		 	Chief Executive Officer

 I have read and accept this amendment to my Existing Offer Letter: 
  

					
	Date: 3-10-2009	 		 	/s/ Hsiao D. Lieu

  

 Page 1Amendment to Offer Letter - Jane Moffitt

 EXHIBIT 10.20 
  

					
	 

	 	 115 Sansome Street, Suite #310
 San Francisco, California 94104
	  	 (415) 415-7880 Tel.
 (415) 875-7075 Fax

 10 March 2009 
 Jane Moffitt 
 460 Nimitz Avenue 
 Redwood City, CA
94061 
  

	Re:	Amendment to Offer Letter 

 Dear Jane: 
 Nile Therapeutics, Inc. (the “Company”) is pleased to offer an amendment to your current terms of employment as set forth in that offer letter
dated April 25, 2008, as amended to date (the “Existing Offer Letter”). Effective upon your agreement with the terms of this letter, the paragraph in the Existing Offer Letter beginning with “For purposes of this letter, a
‘Change in Control’ shall mean . . .” shall be amended and restated in its entirety to read as follows: 
 For purposes of this
letter, a “Change in Control” shall mean a transaction or series of transactions (other than an offering of the Company’s stock to the general public through a registration statement filed with the Securities and Exchange Commission)
whereby any “person” or related “group” of “persons” (as such terms are used in Sections 13(d) and 14(d)(2) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (other than the Company, any
of its subsidiaries, an employee benefit plan maintained by the Company or any of its subsidiaries or a “person” that, prior to such transaction, directly or indirectly controls, is controlled by, or is under common control with, the
Company) directly or indirectly acquires beneficial ownership (within the meaning of Rule 13d-3 under the Exchange Act) of securities of the Company possessing more than 50% of the total combined voting power of the Company’s securities
outstanding immediately after such acquisition. Notwithstanding the foregoing, no transaction shall be considered a Change of Control for the purposes of this letter: (A) if the stockholders existing prior to such transaction(s) hold in the
aggregate more than fifty percent (50%) of the securities or assets of the surviving or resulting company; or (B) in connection with a private placement of equity securities of the Company in connection with a financing of the
Company’s on-going operations. 
 While the Existing Offer Letter with be amended and restated as set forth above, the remainder of your
Existing Offer Letter shall otherwise remain unchanged and in full force and effect. Please indicate your agreement with these terms by signing and dating the enclosed duplicated original of this letter agreement and returning it to me. 

 

			
	Sincerely,
	
	Nile Therapeutics, Inc.
		
	By:	 	/s/ Peter Strumph
		 	Peter Strumph
		 	Chief Executive Officer

 I have read and accept this amendment to my Existing Offer Letter: 
  

					
	Date: 10 March 2009	 		 	/s/ Jane Moffitt

  

 Page 1Agreement

 Exhibit 10.2 
 December 4, 2008 
 Steve Filton 
 Senior Vice
President & CFO 
 UHS of Delaware, Inc. 
 367 South
Gulph Road 
 King of Prussia, PA 19406 
 Dear Steve; 

The Board of Trustees of Universal Health Realty Income Trust, at their December 4, 2008 meeting, authorized the renewal of the current Advisory
Agreement between the Trust and UHS of Delaware, Inc. (“Agreement”) upon the same terms and conditions. 
 This letter constitutes
the Trust’s offer to renew the Agreement, until December 31, 2009, upon the same terms and conditions. Please acknowledge UHS of Delaware’s acceptance of this offer by signing in the space provided below and returning one copy of this
letter to me. Thank you. 
  

			
	Sincerely,
	
	/s/ Cheryl K. Ramagano
	Cheryl K. Ramagano
	Vice President & Treasurer
	
	Agreed and Accepted:
	
	UHS OF DELAWARE, INC.
		
	By:	 	/s/ Steve Filton
		 	Steve Filton
		 	Senior Vice President and CFO
	
	cc:        Charles BoyleDirectors' Compensation

 Exhibit 10.5 
 Directors’ Compensation 
 All non-employee directors of the Bank and Trust Company receive $400 and $250, respectively, for each board
meeting they attend. The non-employee directors of the Bank and Trust Company receive $150 for each committee meeting they attend. In addition, non-employee directors of the Bank and Trust Company are paid an annual retainer fee of $8,000 and
$3,000, respectively, except that directors serving on the Bank board who also serve on the Trust Company board receive an additional $1,000 instead of $3,000 annual retainer for serving on the Trust Company board. In addition, the Chairman of the
Audit Committee of the Company Board is paid an additional $2,000 retainer fee. All Company directors have been elected as directors of the Bank, but there is no assurance that this practice will continue. However, not all Company directors serve as
directors of the Trust Company. There are no additional fees paid for being a Company director. 
 The Company also pays for all directors and their spouses
to attend regular director seminars. 
 Non-employee directors were eligible to receive non-qualified stock options under the Company’s 1998 Stock
Option Plan, although that plan expired on March 9, 2008, and no further awards may be granted under the plan.Base Salaries of Executive Officers of the Registrant

 Exhibit 10.6 
 Base Salaries of Executive Officers of the Registrant 
 As of March 1, 2009, the following are the base salaries (on an
annual basis) of the executive officers (as defined in Item 402 (a)(3) of Regulation S-K) of Old Point Financial Corporation: 
  

				
	 Robert F. Shuford
Chairman, President & Chief Executive Officer
Old Point Financial Corporation
	  	$	300,000
	  		
	  		
		
	 Louis G. Morris
Executive Vice President/OPNB
Old Point Financial Corporation
	  	$	250,000
	  		
	  		
		
	 Robert F. Shuford, Jr.
Senior Vice President/Operations
Old Point Financial Corporation
	  	$	167,500
	  		
	  		
		
	 Joseph R. Witt
Senior Vice President/Corporate Banking
Old Point Financial Corporation
	  	$	158,500
	  		
	  		
		
	 Melissa L. Burroughs
Senior Vice President/Lending & Business Development
Old Point Financial
Corporation
	  	$	152,500
	  		
	  		
		
	 Margaret P. Causby
Senior Vice President/Risk Management
Old Point Financial Corporation
	  	$	151,500
	  		
	  		
		
	 Laurie D. Grabow
Chief Financial Officer & Senior Vice President/Finance
Old Point Financial
Corporation
	  	$	150,000
	  		
	  		
		
	 Eugene M. Jordan, II
Executive Vice President/Trust
Old Point Financial Corporation
	  	$	150,000Description of Management Incentive Plan

 Exhibit 10.7 
 Description of Management Incentive Plan 
 The Management Incentive Plan is an annual bonus incentive plan designed
to motivate and reward participants for the achievement of fiscal year financial and non-financial objectives that directly contribute to the overall success of the Company. Non-commissioned exempt employees, except the CEO, hired no later than the
last day of the prior year and employed through year-end of the current year are eligible to participate in the annual bonus incentive plan. This plan includes all of the Company’s NEO’s except the CEO. 
 At the beginning of each year, the Board of Directors establishes bonus targets and performance goals under the plan for the year. Bonus award payouts under the plan are
objectively determined, based on achievement of the established financial goals such as deposit, loan and income growth during the year. The Board of Directors has discretion to increase or decrease the award based on non-financial goal
achievements. The bonus award payouts under the plan are determined before the end of the year and are based on actual year-to-date and estimated end-of-year performance of the established goals. To do this, the Board of Directors reviews a list of
various projects and the completion status in November of each year, and based on the status of these projects to the goal established at the beginning of the year, determines the non-financial goal achievement level. 
 The target incentive award is the amount that the participant is eligible to receive if the combined, weighted performance against the plan objectives equals an overall
achievement level based on the operating budget. The target incentive award percentage range varies based on the participant’s officer level in the Company.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00155-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00155-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00155-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00155-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00155-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00155-of-00352.parquet"}]]